myCOPD for self-management of chronic obstructive pulmonary disease (MIB214)
NICE has developed a medtech innovation briefing (MIB) on myCOPD for self-management of chronic obstructive pulmonary disease
Search results
132 results
-
-
Remsima (infliximab biosimilar) for subcutaneous injection for managing Crohn's disease and ulcerative colitis (ES35)
Summary of the evidence on remsima (infliximab biosimilar) for subcutaneous injection for managing Crohn’s disease and ulcerative colitis
-
COVID-19 rapid evidence summary: Tocilizumab for COVID-19 (ES33)
ES33 Product overview The content of this evidence summary was up to date in February 2021. New evidence may have been
-
Chronic obstructive pulmonary disease: beclometasone, formoterol and glycopyrronium (Trimbow) (ES17)
Summary of the evidence on beclometasone, formoterol and glycopyrronium (Trimbow) for chronic obstructive pulmonary disease (COPD) to inform local NHS planning
-
Antimicrobial prescribing: delafloxacin for acute bacterial skin and skin structure infections (ES32)
Summary of the evidence on antimicrobial prescribing: delafloxacin
-
Antimicrobial prescribing: cefiderocol (ES31)
Summary of the evidence on antimicrobial prescribing: cefiderocol
-
COVID-19 rapid evidence summary: Sarilumab for COVID-19 (ES34)
ES34 Product overview The content of this evidence summary was up to date in January 2021. New evidence may have been
-
COVID-19 rapid evidence summary: acute use of non-steroidal anti-inflammatory drugs (NSAIDs) for people with or at risk of COVID-19 (ES23)
ES23 . Key messages The content of this evidence review was up to date on 24 March 2020. New evidence may have been published since
-
COVID 19 rapid evidence summary: Anakinra for COVID-19 associated secondary haemophagocytic lymphohistiocytosis (ES26)
ES26 . Key messages The content of this evidence review was up to date on 13 May 2020. New evidence may have been published since
-
COVID-19 rapid evidence summary: Remdesivir for treating hospitalised patients with suspected or confirmed COVID-19 (ES27)
ES27 . Key messages The content of this evidence review was up to date on 4 June 2020. New evidence has been published since then
-
COVID-19 rapid evidence summary: angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) in people with or at risk of COVID-19 (ES24)
ES24 . Key messages The content of this evidence review was up to date on 1 April 2020. New evidence may have been published since
-
COVID-19 rapid evidence summary: Long-term use of non-steroidal anti-inflammatory drugs (NSAIDs) for people with or at risk of COVID-19 (ES25)
ES25 . Key messages The content of this evidence review was up to date on 20 April 2020. New evidence may have been published since
-
Chronic obstructive pulmonary disease: fluticasone furoate, umeclidinium and vilanterol (Trelegy) (ES18)
Summary of the evidence on fluticasone furoate, umeclidinium and vilanterol (Trelegy) for chronic obstructive pulmonary disease (COPD) to inform local NHS
-
Opioid dependence: buprenorphine prolonged-release injection (Buvidal) (ES19)
Summary of the evidence on buprenorphine prolonged-release subcutaneous injection (Buvidal) for opioid dependence to inform local NHS
-
Doxylamine/pyridoxine (Xonvea) for treating nausea and vomiting of pregnancy (ES20)
Summary of the evidence on doxylamine/pyridoxine (Xonvea) for treating nausea and vomiting of pregnancy in women aged 18 years and older to inform local NHS
-
Antimicrobial prescribing: meropenem with vaborbactam (ES21)
Summary of the evidence on antimicrobial prescribing of meropenem with vaborbactam (Vaborem) to inform local NHS planning and decision making
-
Antimicrobial prescribing: ceftolozane with tazobactam for treating hospital-acquired pneumonia, including ventilator-associated pneumonia (ES22)
Summary of the evidence on the antimicrobial prescribing of ceftolozane with tazobactam for hospital-acquired pneumonia, including ventilator-associated
-
Remsima (infliximab biosimilar) for subcutaneous injection for managing rheumatoid arthritis (ES29)
Summary of the evidence on remsima (infliximab biosimilar) for subcutaneous injection for managing rheumatoid arthritis
-
Antimicrobial prescribing: imipenem with cilastatin and relebactam (ES30)
Summary of the evidence on antimicrobial prescribing: imipenem with cilastatin and relebactam
-
Narrow band imaging for Barrett's oesophagus (MIB179)
Advice on narrow band imaging for Barrett's oesophagus to aid local decision making
-
ADXBLADDER for detecting bladder cancer (MIB180)
NICE has developed a medtech innovation briefing (MIB) on ADXBLADDER for detecting bladder cancer
-
LiverMultiScan for liver disease (MIB181)
NICE has developed a medtech innovation briefing (MIB) on LiverMultiScan for liver disease
-
The Vest for delivering high-frequency chest wall oscillation in people with complex neurological needs (MIB159)
NICE has developed a medtech innovation briefing (MIB) on The Vest for delivering high-frequency chest wall oscillation in people with complex neurological need
-
Servo-n with Neurally Adjusted Ventilatory Assist (NAVA) for babies and children (MIB163)
NICE has developed a medtech innovation briefing (MIB) on Serve-n with Neurally Adjusted Ventilatory Assist (NAVA) for babies and children
-
Cerebrotech Visor for detecting stroke (MIB165)
NICE has developed a medtech innovation briefing (MIB) on Cerebrotech Visor for detecting stroke
-
QAngio XA 3D/QFR imaging software for assessing coronary obstructions (MIB146)
NICE has developed a medtech innovation briefing (MIB) on QAngio XA 3D/QFR imaging software for assessing coronary obstructions
-
AlignRT for intracranial stereotactic radiosurgery (MIB147)
NICE has developed a medtech innovation briefing (MIB) on AlignRT for intracranial stereotactic radiosurgery
-
VIDAvision for lung volume analysis in emphysema (MIB148)
NICE has developed a medtech innovation briefing (MIB) on VIDAvision for lung volume analysis in emphysema
-
ORA G3 to measure corneal hysteresis (MIB150)
NICE has developed a medtech innovation briefing (MIB) on ORA G3 to measure corneal hysteresis
-
Peezy Midstream for urine collection (MIB183)
NICE has developed a medtech innovation briefing (MIB) on Peezy Midstream for urine collection
-
DuraGraft for preserving vascular grafts (MIB184)
NICE has developed a medtech innovation briefing (MIB) on DuraGraft for preserving vascular grafts
-
Danis stent for acute oesophageal variceal bleeds (MIB185)
NICE has developed a medtech innovation briefing (MIB) on Danis stent for acute oesophageal variceal bleeds
-
The OPTIMIZER smart system for managing heart failure (MIB186)
NICE has developed a medtech innovation briefing (MIB) on the OPTIMIZER smart system for managing heart failure
-
Natural Cycles for monitoring fertility (MIB244)
NICE has developed a medtech innovation briefing (MIB) on Natural Cycles for monitoring fertility
-
Optilume for anterior urethral strictures (MIB241)
NICE has developed a medtech innovation briefing (MIB) on Optilume for anterior urethral strictures
-
Artificial intelligence for analysing chest CT images (MIB243)
NICE has developed a medtech innovation briefing (MIB) on artificial intelligence for analysing chest CT images
-
Optowire for measuring fractional flow reserve (MIB199)
NICE has developed a medtech innovation briefing (MIB) on Optowire for measuring fractional flow reserve
-
PIUR tUS for abdominal aortic aneurysm surveillance and endovascular aneurysm repair endoleak detection (MIB200)
NICE has developed a medtech innovation briefing (MIB) on PIUR tUS for abdominal aortic aneurysm surveillance and endovascular aneurysm repair endoleak
-
eXroid for internal haemorrhoids (MIB201)
NICE has developed a medtech innovation briefing (MIB) on eXroid for internal haemorrhoids
-
PulmoVista 500 for monitoring ventilation in critical care (MIB203)
NICE has developed a medtech innovation briefing (MIB) on PulmoVista 500 for monitoring ventilation in critical care
-
Plus Sutures for preventing surgical site infection (MIB204)
NICE has developed a medtech innovation briefing (MIB) on Plus Sutures for preventing surgical site infection
-
TUC Safety Valve to prevent balloon inflation in the urethra during transurethral catheterisation (MIB210)
NICE has developed a medtech innovation briefing (MIB) on TUC Safety Valve to prevent balloon inflation in the urethra during transurethral catheterisation
-
Archimedes for biopsy of suspected lung cancer (MIB211)
NICE has developed a medtech innovation briefing (MIB) on Archimedes for biopsy of suspected lung cancer
-
MolecuLight i:X for wound imaging (MIB212)
NICE has developed a medtech innovation briefing (MIB) on MolecuLight i:X for wound imaging
-
Lifelight First for monitoring vital signs (MIB213)
NICE has developed a medtech innovation briefing (MIB) on Lifelight First for monitoring vital signs
-
Space from Depression for treating adults with depression (MIB215)
NICE has developed an Improving Access to Psychological Therapies (IAPT) report on Space from Depression for treating adults with depression
-
FibroScan for assessing liver fibrosis and cirrhosis in primary care (MIB216)
NICE has developed a medtech innovation briefing (MIB) on FibroScan for assessing liver fibrosis and cirrhosis in primary care
-
Cytokine adsorption devices for treating respiratory failure in people with COVID-19 (MIB217)
NICE has developed a medtech innovation briefing (MIB) on cytokine adsorption devices for treating respiratory failure in people with COVID-19
-
Cor-Knot for tying suture knots in valve surgery (MIB206)
NICE has developed a medtech innovation briefing (MIB) on Cor-Knot for tying suture knots in valve surgery
-
Galaxy UNYCO for temporary stabilisation of lower limb fractures (MIB166)
NICE has developed a medtech innovation briefing (MIB) on Galaxy UNYCO for temporary stabilisation of lower limb fractures